Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-14 4:21 pm Sale | 2023-12-31 | 13G | Mirati Therapeutics, Inc. MRTX | Baker Bros. Advisors LP | 0 0.000% | -1,995,200 (Position Closed) | Filing History |
| 2024-02-14 4:21 pm Purchase | 2023-12-31 | 13G | Adaptimmune Therapeutics plc ADAPY | Baker Bros. Advisors LP | 65,815,692 4.800% | 6,830,430 (+11.58%) | Filing History |
| 2024-02-14 4:21 pm Sale | 2023-12-31 | 13G | Aerovate Therapeutics, Inc. AVTE | Baker Bros. Advisors LP | 48,015 6.100% | -8,467 (-14.99%) | Filing History |
| 2024-02-14 4:21 pm Unchanged | 2023-12-31 | 13G | Spyre Therapeutics, Inc. SYRE | Baker Bros. Advisors LP | 0 0.000% | 0 (Unchanged) | Filing History |
| 2024-02-14 4:21 pm Purchase | 2023-12-31 | 13G | Aligos Therapeutics, Inc. ALGS | Baker Bros. Advisors LP | 146,561 4.990% | 63,505 (+76.46%) | Filing History |
| 2024-02-14 4:21 pm Sale | 2023-12-31 | 13G | Aravive, Inc. ARAV | Baker Bros. Advisors LP | 3,863,568 4.990% | -722,836 (-15.76%) | Filing History |
| 2024-02-14 4:21 pm Purchase | 2023-12-31 | 13G | Cabaletta Bio, Inc. CABA | Baker Bros. Advisors LP | 1,457,626 3.400% | 113,626 (+8.45%) | Filing History |
| 2024-02-14 4:21 pm Unchanged | 2023-12-31 | 13G | Akero Therapeutics, Inc. AKRO | Baker Bros. Advisors LP | 2,368,378 4.300% | 0 (Unchanged) | Filing History |
| 2024-02-14 4:21 pm Sale | 2023-12-31 | 13G | Heron Therapeutics, Inc. HRTX | Baker Bros. Advisors LP | 7,881,933 4.990% | -249,745 (-3.07%) | Filing History |
| 2024-02-14 4:21 pm Sale | 2023-12-31 | 13G | CYTEIR THERAPEUTICS INC CYTT | Baker Bros. Advisors LP | 0 0.000% | -2,492,118 (Position Closed) | Filing History |
| 2024-02-14 4:21 pm Purchase | 2023-12-31 | 13G | Cerus Corporation CERS | Baker Bros. Advisors LP | 19,497,203 10.800% | 395,327 (+2.07%) | Filing History |
| 2024-02-14 4:21 pm Purchase | 2023-12-31 | 13G | HOOKIPA Pharma Inc. HOOK | Baker Bros. Advisors LP | 814,899 9.990% | 467,345 (+134.47%) | Filing History |
| 2024-02-14 4:21 pm Purchase | 2023-12-31 | 13G | Immatics N.V. IMTX | Baker Bros. Advisors LP | 5,838,853 6.900% | 651,772 (+12.57%) | Filing History |
| 2024-02-14 4:21 pm Purchase | 2023-12-31 | 13G | Monte Rosa Therapeutics, Inc. GLUE | Baker Bros. Advisors LP | 4,916,095 9.800% | 4,916,095 (New Position) | Filing History |
| 2024-02-14 4:21 pm Purchase | 2023-12-31 | 13G | Nurix Therapeutics, Inc. NRIX | Baker Bros. Advisors LP | 4,952,452 9.990% | 150,498 (+3.13%) | Filing History |
| 2024-02-14 4:21 pm Sale | 2023-12-31 | 13G | OPTHEA LTD SPONSORED ADR OPTEY | Baker Bros. Advisors LP | 28,100,345 4.200% | -3,527,499 (-11.15%) | Filing History |
| 2024-02-14 4:21 pm Purchase | 2023-12-31 | 13G | Rhythm Pharmaceuticals, Inc. RYTM | Baker Bros. Advisors LP | 6,398,365 10.800% | 43,757 (+0.69%) | Filing History |
| 2024-02-14 4:21 pm Purchase | 2023-12-31 | 13G | Sagimet Biosciences Inc. SGMT | Baker Bros. Advisors LP | 1,456,518 6.800% | 1,456,518 (New Position) | Filing History |
| 2024-02-14 4:21 pm Sale | 2023-12-31 | 13G | Ascendis Pharma A/S ASND | Baker Bros. Advisors LP | 0 0.000% | -4,954,855 (Position Closed) | Filing History |
| 2024-02-14 4:21 pm Purchase | 2023-12-31 | 13G | Athira Pharma, Inc. ATHA | Baker Bros. Advisors LP | 315,381 8.300% | 315,381 (New Position) | Filing History |